Severe allergic eye disease: What to do and when?

Annegret Dahlmann-Noor^{1

2}, Kirithika Muthusamy³, Melanie Hingorani^{2

3}

Affiliations

Editorial

Annegret Dahlmann-Noor et al. Clin Exp Allergy. 2021 Aug.

. 2021 Aug;51(8):989-991.

doi: 10.1111/cea.13985.

Annegret Dahlmann-Noor^{1

2}, Kirithika Muthusamy³, Melanie Hingorani^{2

3}

No abstract available

References

1. Roumeau I, Coutu A, Navel V, et al. Efficacy of medical treatments for vernal keratoconjunctivitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2021;S0091-6749(21):00548. https://doi.org/10.1016/j.jaci.2021.03.026
1. Kim SE, Nowak V, Quartilho A, et al. Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years. Cochrane Database Syst Rev. 2020;10(10):CD013298. https://doi.org/10.1002/14651858.CD013298.pub2
1. Leonardi A, Silva D, Perez Formigo D, et al. Management of ocular allergy. Allergy. 2019;74:1611-1630. https://doi.org/10.1111/all.13786
1. Leonardi A, Doan S, Amrane M, et al. A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study. Ophthalmology. 2019;126:671-681. https://doi.org/10.1016/j.ophtha.2018.12.027
1. Bremond-Gignac D, Doan S, Amrane M, et al. Twelve-month results of cyclosporine A cationic emulsion in a randomized study in patients with pediatric vernal keratoconjunctivitis. Am J Ophthalmol. 2020;212:116-126. https://doi.org/10.1016/j.ajo.2019.11.020